First Light Diagnostics
First Light Diagnostics is dedicated to providing rapid, sensitive, and cost-effective diagnostic solutions for life-threatening hospital infections. Leveraging its proprietary MultiPath technology, the company aims to dramatically accelerate pathogen detection and antimicrobial susceptibility testing, enabling clinicians to make faster, more informed treatment decisions. Its mission is to save lives, lower healthcare costs, and combat antibiotic resistance by delivering results in hours instead of days.
Industries
Nr. of Employees
small (1-50)
First Light Diagnostics
Bedford, Massachusetts, United States, North America
Products
Fully automated benchtop sample-to-answer analyzer
A random-access benchtop instrument that automates sample loading, assay execution, barcode reading, results reporting, and disposal for cartridge-based tests; designed for on-demand, multi-sample workflows.
Rapid Clostridioides difficile toxin detection test (FDA-cleared)
An ultra-sensitive toxin B detection assay for stool specimens that reports rapid results and is intended to improve specificity for active infection compared to molecular detection of organism presence.
Rapid Bacillus anthracis toxin detection test (FDA-cleared)
A rapid, sensitive assay for detection of Bacillus anthracis toxin (lethal factor) in blood samples intended for early diagnosis of inhalation anthrax; reported FDA clearance to market in the U.S.
Direct-from-urine pathogen identification and phenotypic AST (peer-reviewed demonstration)
Published peer-reviewed demonstration of direct-from-urine pathogen identification (reported ~45 minutes) and phenotypic AST (reported <5 hours) without colony isolation.
Fully automated benchtop sample-to-answer analyzer
A random-access benchtop instrument that automates sample loading, assay execution, barcode reading, results reporting, and disposal for cartridge-based tests; designed for on-demand, multi-sample workflows.
Rapid Clostridioides difficile toxin detection test (FDA-cleared)
An ultra-sensitive toxin B detection assay for stool specimens that reports rapid results and is intended to improve specificity for active infection compared to molecular detection of organism presence.
Rapid Bacillus anthracis toxin detection test (FDA-cleared)
A rapid, sensitive assay for detection of Bacillus anthracis toxin (lethal factor) in blood samples intended for early diagnosis of inhalation anthrax; reported FDA clearance to market in the U.S.
Direct-from-urine pathogen identification and phenotypic AST (peer-reviewed demonstration)
Published peer-reviewed demonstration of direct-from-urine pathogen identification (reported ~45 minutes) and phenotypic AST (reported <5 hours) without colony isolation.
Services
Analytical validation and publication support
Conducting technical studies, posters, and peer-reviewed publications demonstrating assay performance for direct-from-specimen ID and phenotypic AST.
Analytical validation and publication support
Conducting technical studies, posters, and peer-reviewed publications demonstrating assay performance for direct-from-specimen ID and phenotypic AST.
Expertise Areas
- Rapid diagnostic assay development
- Phenotypic antimicrobial susceptibility testing
- Ultra-sensitive toxin and biomarker detection
- Sample-to-answer automation and random-access benchtop systems
Key Technologies
- Non-magnified digital imaging
- Single-molecule counting via digital imaging
- Fluorescence labeling with optical sequestration (dye-cushion)
- Cartridge-based disposable assay consumables